Literature DB >> 25009140

NMR spectroscopy reveals a preferred conformation with a defined hydrophobic cluster for polyglutamine binding peptide 1.

Francisco Ramos-Martín1, Rubén Hervás1, Mariano Carrión-Vázquez1, Douglas V Laurents2.   

Abstract

Several important human inherited neurodegenerative diseases are caused by "polyQ expansions", which are aberrant long repeats of glutamine residues in proteins. PolyQ binding peptide 1 (QBP1), whose minimal active core sequence is Trp-Lys-Trp-Trp-Pro-Gly-Ile-Phe, binds to expanded polyQs and blocks their β-structure transition, aggregation and in vivo neurodegeneration. Whereas QBP1 is a widely used, commercially available product, its structure is unknown. Here, we have characterized the conformations of QBP1 and a scrambled peptide (Trp-Pro-Ile-Trp-Lys-Gly-Trp-Phe) in aqueous solution by CD, fluorescence and NMR spectroscopies. A CD maximum at 227 nm suggests the presence of rigid Trp side chains in QBP1. Based on 41 NOE-derived distance constraints, the 3D structure of QBP1 was determined. The side chains of Trp 4 and Ile 7, and to a lesser extent, those of Lys 2, Trp 3 and Phe 8, form a small hydrophobic cluster. Pro 5 and Gly 6 adopt a type II tight turn and Lys 2's ζ-NH3(+) is positioned to form a favorable cation-π interaction with Trp 4's indole ring. In contrast, the scrambled QBP1 peptide, which lacks inhibitory activity, does not adopt a preferred structure. These results provide a basis for future structure-based design approaches to further optimize QBP1 for therapy.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Amyloid inhibitor; CAG-expansion diseases; Nuclear magnetic resonance; Protein misfolding & aggregation

Mesh:

Substances:

Year:  2014        PMID: 25009140     DOI: 10.1016/j.abb.2014.06.025

Source DB:  PubMed          Journal:  Arch Biochem Biophys        ISSN: 0003-9861            Impact factor:   4.013


  4 in total

1.  Divergent CPEB prion-like domains reveal different assembly mechanisms for a generic amyloid-like fold.

Authors:  Rubén Hervás; María Del Carmen Fernández-Ramírez; Albert Galera-Prat; Mari Suzuki; Yoshitaka Nagai; Marta Bruix; Margarita Menéndez; Douglas V Laurents; Mariano Carrión-Vázquez
Journal:  BMC Biol       Date:  2021-03-11       Impact factor: 7.431

2.  Assessing a peptidylic inhibitor-based therapeutic approach that simultaneously suppresses polyglutamine RNA- and protein-mediated toxicities in patient cells and Drosophila.

Authors:  Qian Zhang; Ho Tsoi; Shaohong Peng; Pan P Li; Kwok-Fai Lau; Dobrila D Rudnicki; Jacky Chi-Ki Ngo; Ho Yin Edwin Chan
Journal:  Dis Model Mech       Date:  2016-02-02       Impact factor: 5.758

3.  Molecular Basis of Orb2 Amyloidogenesis and Blockade of Memory Consolidation.

Authors:  Rubén Hervás; Liying Li; Amitabha Majumdar; María Del Carmen Fernández-Ramírez; Jay R Unruh; Brian D Slaughter; Albert Galera-Prat; Elena Santana; Mari Suzuki; Yoshitaka Nagai; Marta Bruix; Sergio Casas-Tintó; Margarita Menéndez; Douglas V Laurents; Kausik Si; Mariano Carrión-Vázquez
Journal:  PLoS Biol       Date:  2016-01-26       Impact factor: 8.029

Review 4.  Protein Misfolding and Aggregation as a Therapeutic Target for Polyglutamine Diseases.

Authors:  Toshihide Takeuchi; Yoshitaka Nagai
Journal:  Brain Sci       Date:  2017-10-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.